- Home
- MIRM vs BLTE Comparison
MIRM vs BLTE Comparison
Compare MIRM & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- BLTE
- Stock Information
- Founded
- MIRM 2018
- BLTE 2018
- Country
- MIRM United States
- BLTE United States
- Employees
- MIRM N/A
- BLTE N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- MIRM Health Care
- BLTE Health Care
- Exchange
- MIRM Nasdaq
- BLTE Nasdaq
- Market Cap
- MIRM 2.5B
- BLTE 2.1B
- IPO Year
- MIRM 2019
- BLTE 2022
- Fundamental
- Price
- MIRM $52.17
- BLTE $61.80
- Analyst Decision
- MIRM Strong Buy
- BLTE Strong Buy
- Analyst Count
- MIRM 9
- BLTE 4
- Target Price
- MIRM $66.22
- BLTE $96.67
- AVG Volume (30 Days)
- MIRM 413.0K
- BLTE 74.0K
- Earning Date
- MIRM 08-06-2025
- BLTE 08-08-2025
- Dividend Yield
- MIRM N/A
- BLTE N/A
- EPS Growth
- MIRM N/A
- BLTE N/A
- EPS
- MIRM N/A
- BLTE N/A
- Revenue
- MIRM $379,251,000.00
- BLTE N/A
- Revenue This Year
- MIRM $35.83
- BLTE N/A
- Revenue Next Year
- MIRM $16.83
- BLTE N/A
- P/E Ratio
- MIRM N/A
- BLTE N/A
- Revenue Growth
- MIRM 69.31
- BLTE N/A
- 52 Week Low
- MIRM $36.20
- BLTE $43.70
- 52 Week High
- MIRM $54.78
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- MIRM 56.47
- BLTE 51.78
- Support Level
- MIRM $50.96
- BLTE $59.12
- Resistance Level
- MIRM $53.59
- BLTE $62.64
- Average True Range (ATR)
- MIRM 1.63
- BLTE 2.29
- MACD
- MIRM -0.17
- BLTE 0.08
- Stochastic Oscillator
- MIRM 53.06
- BLTE 52.12
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.